Nobivac Myxo-RHD
live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Nobivac Myxo-RHD
|
Agency product number |
EMEA/V/C/002004
|
Active substance |
live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009
|
International non-proprietary name (INN) or common name |
live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009
|
Species |
Rabbits
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI08AD
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
07/09/2011
|
Contact address |
Wim de Körverstraat 35
5831 AN Boxmeer Netherlands |
Product information
18/03/2021 Nobivac Myxo-RHD - EMEA/V/C/002004 - IG/1348
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of rabbits from five weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease.
Onset of immunity: 3 weeks.
Duration of immunity: 1 year.